Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications
Cancers · 28.02.2023 · 15 (5) · 1518
DOI: 10.3390/cancers15051518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.02.2023. Verfasst von Cinzia Baldessari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Azienda Ospedaliero Universitaria of Modena, 41125 Modena, Italy. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone metastases start with the tropism of cancer cells to the bone through different multi-step tumor–host interactions, as described by the “metastatic cascade” model. Understanding these mechanisms, although far from being fully elucidated, could offer several potential targets for prevention and therapy. Moreover, the prognosis of patients is markedly influenced by skeletal-related events. They can be correlated not only with bone metastases, but also with “bad” bone health. There is a close correlation between osteoporosis—a skeletal disorder with decreased bone mass and qualitative alterations—and prostate cancer, in particular when treated with androgen deprivation therapy, a milestone in its treatment. Systemic treatments for prostate cancer, especially with the newest options, have improved the survival and quality of life of patients with respect to skeletal-related events; however, all patients should be evaluated for “bone health” and osteoporotic risk, both in the presence and in the absence of bone metastases. Treatment with bone-targeted therapies should be evaluated even in the absence of bone metastases, as described in special guidelines and according to a multidisciplinary evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology and Hematology, Azienda Ospedaliero Universitaria of Modena, 41125 Modena, Italy.
- Oncology, AUSL of Modena Area Sud, Sassuolo-Vignola-Pavullo, 41121 Modena, Italy.
- Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
- Department of Oncology, Azienda Ospedaliero Universitaria S. M. della Misericordia, 33100 Udine, Italy.
- Medical Oncology, Ospedale Santa Corona, 17027 Pietra Ligure, Italy.
- Department of Oncology and Hematology, Univerity of Modena and Reggio Emilia, 41125 Modena, Italy.
ORCID-Profile: Cinzia Baldessari, Eleonora Molinaro, Martina Fanelli, Giuseppe Pugliese, Maria Giuseppa Vitale
Zitieren
APA
Baldessari, C., Pipitone, S., Molinaro, E., Cerma, K., Fanelli, M., Nasso, C., Oltrecolli, M., Pirola, M., D'Agostino, E., Pugliese, G., Cerri, S., Vitale, M. G., Madeo, B., Dominici, M., & Sabbatini, R. (2023). Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. Cancers, 15(5), 1518. https://doi.org/10.3390/cancers15051518
Vancouver
Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C, et al. Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. Cancers. 2023;15(5):1518. doi:10.3390/cancers15051518
BibTeX
@article{Baldessari2023,
author = {Baldessari, Cinzia and Pipitone, Stefania and Molinaro, Eleonora and Cerma, Krisida and Fanelli, Martina and Nasso, Cecilia and Oltrecolli, Marco and Pirola, Marta and D'Agostino, Elisa and Pugliese, Giuseppe and Cerri, Sara and Vitale, Maria Giuseppa and Madeo, Bruno and Dominici, Massimo and Sabbatini, Roberto},
title = {Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications},
journal = {Cancers},
year = {2023},
volume = {15},
number = {5},
pages = {1518},
doi = {10.3390/cancers15051518}
}
EUVIMED